COX-2 MEDIATES PRO-TUMORIGENIC EFFECTS OF PKCε IN PROSTATE CANCER
暂无分享,去创建一个
T. Grosser | M. Feldman | J. Blando | E. Ricciotti | P. Lal | M. Kazanietz | R. Garg | E. Smyth | F. Benavides | Carlos J. Pérez | Rachana Garg
[1] Yanlong Yang,et al. The prognostic value of cyclooxygenase-2 expression in patients with esophageal cancer: evidence from a meta-analysis , 2017, OncoTargets and therapy.
[2] J. Blando,et al. Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway. , 2017, Cell reports.
[3] Andrew H. Beck,et al. Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling. , 2017, Cancer research.
[4] E. Dirican. Mutations in PIK3CA Sensitize Breast Cancer Cells to Physiologic Levels of Aspirin. , 2016, Asian Pacific journal of cancer prevention : APJCP.
[5] A. Houston,et al. Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? , 2015, British journal of pharmacology.
[6] R. Santi,et al. mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity , 2015, Endocrine-related cancer.
[7] M. Kazanietz,et al. PKCϵ Is an Essential Mediator of Prostate Cancer Bone Metastasis , 2015, Molecular Cancer Research.
[8] M. Kazanietz,et al. Protein kinase C and cancer: what we know and what we do not , 2014, Oncogene.
[9] M. Kazanietz,et al. Transcriptional Regulation of Oncogenic Protein Kinase Cϵ (PKCϵ) by STAT1 and Sp1 Proteins* , 2014, The Journal of Biological Chemistry.
[10] R. Gomis,et al. Cyclooxygenase‐2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice , 2014, BJU international.
[11] A. Basu,et al. The Multifunctional Protein Kinase C-ε in Cancer Development and Progression , 2014, Cancers.
[12] F. Sinicrope,et al. Aspirin and Colorectal Cancer: Back to the Future , 2013, Clinical Cancer Research.
[13] V. Budhram-Mahadeo,et al. Protein Kinase Cε-Calcineurin Cosignaling Downstream of Toll-Like Receptor 4 Downregulates Fibrosis and Induces Wound Healing Gene Expression in Cardiac Myofibroblasts , 2013, Molecular and Cellular Biology.
[14] T. Uchiumi,et al. EP2 signaling mediates suppressive effects of celecoxib on androgen receptor expression and cell proliferation in prostate cancer , 2013, Prostate Cancer and Prostatic Disease.
[15] R. Dingledine,et al. Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. , 2013, Trends in pharmacological sciences.
[16] M. Kazanietz,et al. Regulation of Transcriptional Networks by PKC Isozymes: Identification of c-Rel as a Key Transcription Factor for PKC-Regulated Genes , 2013, PloS one.
[17] T. Uchiumi,et al. Prostaglandin receptor EP3 mediates growth inhibitory effect of aspirin through androgen receptor and contributes to castration resistance in prostate cancer cells. , 2013, Endocrine-related cancer.
[18] T. Tammela,et al. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. , 2013, European journal of cancer.
[19] R. Dingledine,et al. Role of Prostaglandin Receptor EP2 in the Regulations of Cancer Cell Proliferation, Invasion, and Inflammation , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[20] A. Takaoka,et al. [NF-kappaB signaling pathway and inflammation]. , 2012, Nihon rinsho. Japanese journal of clinical medicine.
[21] Reiko Nishihara,et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. , 2012, The New England journal of medicine.
[22] J. Blando,et al. Activation of Nuclear Factor κB (NF-κB) in Prostate Cancer Is Mediated by Protein Kinase C ϵ (PKCϵ)* , 2012, The Journal of Biological Chemistry.
[23] Randall Harris,et al. Reduction in cancer risk by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors , 2012, Journal of experimental pharmacology.
[24] G. Robertson,et al. Selenium-containing histone deacetylase inhibitors for melanoma management , 2012, Cancer biology & therapy.
[25] M. Kazanietz,et al. Proteins kinase Cɛ is required for non-small cell lung carcinoma growth and regulates the expression of apoptotic genes , 2012, Oncogene.
[26] M. Parmar,et al. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial , 2012, The Lancet. Oncology.
[27] A. Armstrong. The STAMPEDE trial and celecoxib: how to adapt? , 2012, The Lancet. Oncology.
[28] J. Moscat,et al. The atypical PKCs in inflammation: NF‐κB and beyond , 2012, Immunological reviews.
[29] J. Kissil,et al. Non-Small Cell Lung Carcinoma Cell Motility, Rac Activation and Metastatic Dissemination Are Mediated by Protein Kinase C Epsilon , 2012, PloS one.
[30] V. Baron,et al. Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo , 2011, The Prostate.
[31] M. Choe,et al. Cyclooxygenase-2 overexpression in chronic inflammation associated with benign prostatic hyperplasia: is it related to apoptosis and angiogenesis of prostate cancer? , 2011, Korean journal of urology.
[32] W. Zhong,et al. Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma. , 2011, Cancer research.
[33] J. Blando,et al. Transgenic overexpression of PKCε in the mouse prostate induces preneoplastic lesions , 2011, Cell cycle.
[34] C. Busch,et al. COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-beta, IL-10 and Ki67. , 2010, Cancer epidemiology.
[35] R. Andreesen,et al. Modular therapy approach in metastatic castration-refractory prostate cancer , 2010, World Journal of Urology.
[36] R. DuBois,et al. The role of COX-2 in intestinal inflammation and colorectal cancer , 2010, Oncogene.
[37] A. Conney,et al. Atorvastatin and Celecoxib in Combination Inhibits the Progression of Androgen-Dependent LNCaP Xenograft Prostate Tumors to Androgen Independence , 2010, Cancer Prevention Research.
[38] M. Hamberg,et al. Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells , 2009, Proceedings of the National Academy of Sciences.
[39] Xiaoren Zhang,et al. NF-κB Signaling Pathway, Inflammation and Colorectal Cancer , 2009, Cellular and Molecular Immunology.
[40] Y. Nagashima,et al. aPKCλ/ι promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6 , 2009, Proceedings of the National Academy of Sciences.
[41] M. Serrano,et al. Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-κB activation and invasive prostate carcinoma , 2009, Proceedings of the National Academy of Sciences.
[42] Y. Miki,et al. Protein kinase Cdelta activates RelA/p65 and nuclear factor-kappaB signaling in response to tumor necrosis factor-alpha. , 2009, Cancer research.
[43] Randall Harris,et al. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung , 2009, Inflammopharmacology.
[44] Michael A Gorin,et al. Protein kinase Cε: an oncogene and emerging tumor biomarker , 2009, Molecular Cancer.
[45] E. Giovannucci,et al. Cyclooxygenase-2 Expression Is an Independent Predictor of Poor Prognosis in Colon Cancer , 2008, Clinical Cancer Research.
[46] Shalini Jain,et al. Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. , 2008, Cancer research.
[47] N. Holden,et al. Phorbol ester-stimulated NF-kappaB-dependent transcription: roles for isoforms of novel protein kinase C. , 2008, Cellular signalling.
[48] Jiaoti Huang,et al. A new prostate cancer therapeutic approach: Combination of androgen ablation with COX‐2 inhibitor , 2008, International journal of cancer.
[49] M. Bosland,et al. Exisulind in Combination with Celecoxib Modulates Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Cyclin D1 against Prostate Carcinogenesis: In vivo Evidence , 2007, Clinical Cancer Research.
[50] D. Grignon,et al. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. , 2007, The Lancet. Oncology.
[51] G. Wilding,et al. Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer. , 2007, Cancer research.
[52] Louise R Howe,et al. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer , 2007, Breast Cancer Research.
[53] Shunyou Wang,et al. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. , 2007, Cancer research.
[54] M. Kazanietz,et al. Protein kinase C and other diacylglycerol effectors in cancer , 2007, Nature Reviews Cancer.
[55] V. Adhami,et al. Combined Inhibitory Effects of Green Tea Polyphenols and Selective Cyclooxygenase-2 Inhibitors on the Growth of Human Prostate Cancer Cells Both In vitro and In vivo , 2007, Clinical Cancer Research.
[56] W. Weichert,et al. Overexpression of cyclooxygenase‐2 in human prostate carcinoma and prostatic intraepithelial neoplasia‐association with increased expression of polo‐like kinase‐1 , 2007, The Prostate.
[57] J. Calixto,et al. Pharmacological and Molecular Characterization of the Mechanisms Involved in Prostaglandin E2-Induced Mouse Paw Edema , 2006, Journal of Pharmacology and Experimental Therapeutics.
[58] N. Narayanan,et al. Adenocarcina of the mouse prostate growth inhibition by celecoxib: Downregulation of transcription factors involved in COX‐2 inhibition , 2006, The Prostate.
[59] L. Lessard,et al. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study , 2005, British Journal of Cancer.
[60] R. Bolli,et al. Role of the Protein Kinase C-&egr;–Raf-1–MEK-1/2–p44/42 MAPK Signaling Cascade in the Activation of Signal Transducers and Activators of Transcription 1 and 3 and Induction of Cyclooxygenase-2 After Ischemic Preconditioning , 2005, Circulation.
[61] S. Merajver,et al. Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. , 2005, Cancer research.
[62] R. I. Carey,et al. Cyclooxygenase‐2 inhibitor celecoxib augments chemotherapeutic drug‐induced apoptosis by enhancing activation of caspase‐3 and ‐9 in prostate cancer cells , 2005, International journal of cancer.
[63] Akihiko Satoh,et al. PKC-δ and -ε regulate NF-κB activation induced by cholecystokinin and TNF-α in pancreatic acinar cells , 2004 .
[64] A. Neugut,et al. Rates of caesarean section and instrumental vaginal delivery in nulliparous women after low concentration epidural infusions or opioid analgesia: systematic review , 2004, British medical journal.
[65] J. Lewin,et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. , 2004, Cancer research.
[66] J. Morrow,et al. The glyceryl ester of prostaglandin E2 mobilizes calcium and activates signal transduction in RAW264.7 cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[67] D. Terrian,et al. Protein Kinase Cε Has the Potential to Advance the Recurrence of Human Prostate Cancer , 2002 .
[68] P. Unger,et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. , 2000, Urology.
[69] T. Hla,et al. Expression of cyclooxygenase‐2 in prostate carcinoma , 2000, Cancer.
[70] K. Seibert,et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. , 2000, Cancer research.
[71] A. Jemal,et al. Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.
[72] J. Pablo,et al. Par‐4とPTENのin vivoにおける同時不活性化は相乗的にNF‐κB活性化と侵襲性前立腺癌を誘導する , 2009 .
[73] Gao Tian-we. Overexpression of cyclooxygenase-2 in human malignant melanoma , 2007 .
[74] Tom S. Price,et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. , 2006, Gastroenterology.
[75] Akihiko Satoh,et al. PKC-delta and -epsilon regulate NF-kappaB activation induced by cholecystokinin and TNF-alpha in pancreatic acinar cells. , 2004, American journal of physiology. Gastrointestinal and liver physiology.
[76] A. Dannenberg,et al. COX-2 Inhibitors for the Prevention of Breast Cancer , 2004, Journal of Mammary Gland Biology and Neoplasia.
[77] D. Terrian,et al. Protein kinase cepsilon has the potential to advance the recurrence of human prostate cancer. , 2002, Cancer research.
[78] D. Bostwick,et al. Over‐expression of cyclooxygenase‐2 in human prostate adenocarcinoma , 2000, The Prostate.